Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10417559 | 0.85 | ALDH1A1 (0.34) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL4342363 | 0.84 | CA12 (0.31) | — | |
| SCHEMBL7719130 | 0.83 | ALDH1A1 (0.33) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL28171164 | 0.80 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL1810891 | 0.78 | CA12 (0.32) | — | |
| SCHEMBL1759468 | 0.76 | CA12 (0.31) | ALOX15 | |
| SCHEMBL3844398 | 0.73 | — | — | |
| SCHEMBL3478214 | 0.73 | CA1 (0.35) | — | |
| SCHEMBL29113577 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL4637401 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937697-B1 | METHOD FOR PRODUCTION OF ISOCYANATOSILANES | MOMENTIVE PERFORMANCE MAT INC (US) | 2013-10-16 | — | — | EP | claimed |
| EP-1885731-B1 | PROCESS FOR THE PRODUCTION OF ISOCYANATOSILANE AND SILYLISOCYANURATE | MOMENTIVE PERFORMANCE MAT INC (US) | 2009-11-11 | — | — | EP | claimed |
| EP-1937697-A2 | METHOD FOR PRODUCTION OF ISOCYANATOSILANES | Momentive Performance Materials Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1885731-A1 | PROCESS FOR THE PRODUCTION OF ISOCYANATOSILANE AND SILYLISOCYANURATE | Momentive Performance Materials Inc. (US) | 2008-02-13 | — | — | EP | claimed |
| EP-1869058-A2 | PROCESS FOR MAKING SILYLISOCYANURATE | General Electric Company (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2007037817-A2 | METHOD FOR PRODUCTION OF ISOCYANATOSILANES | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2007-04-05 | — | — | WO | claimed |
| WO-2006132799-A1 | PROCESS FOR THE PRODUCTION OF ISOCYANATOSILANE AND SILYLISOCYANURATE | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2006-12-14 | — | — | WO | claimed |
| WO-2006113182-A2 | PROCESS FOR MAKING SILYLISOCYANURATE | GENERAL ELECTRIC COMPANY (US) | 2006-10-26 | — | — | WO | claimed |
| US-20060235221-A1 | Process for making silylisocyanurate | MOMENTIVE PERFORMANCE MATERIALS INC. | 2006-10-19 | — | — | US | claimed |
| US-7060849-B1 | Method for production of isocyanatosilanes | GENERAL ELECTRIC COMPANY (US) | 2006-06-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235221-A1 | Process for making silylisocyanurate | PCMT1, SRM, STOM | ALDH1A1 2357/4885LMNA 2282/4885HSD17B10 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.